Halozyme Therapeutics (HALO)
NASDAQ:HALO
Want to see HALO full AI Analyst Report?
Earnings Data
Report Date
Aug 11, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.81Last Year’s EPS
1.54Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong, broad-based commercial and financial momentum: double-digit growth across top-line, royalties, adjusted EBITDA and EPS with reaffirmed 2026 guidance, new $1B buyback, and multiple near- and long-term revenue drivers (ENHANZE expansion, Hypercon, Surf Bio and new CLAs). Key near-term challenges include higher leverage and increased operating expenses from recent acquisitions, and manufacturing/timing execution risk for Hypercon and continued reliance on co-formulation IP to extend royalty duration. On balance, the positive metrics, clear capital allocation plans and pipeline/deal momentum outweigh these operational and timing risks.Company Guidance
Strong Top-Line Growth
Total revenue of $376.7M (reported as $377M) in Q1 2026, up ~42% year-over-year, driven by broad-based strength across commercial products and product sales to partners.
Robust Royalty Revenue
Royalty revenue of $240.7M (reported as $241M) in Q1 2026, up ~43% year-over-year, reflecting continued adoption of ENHANZE-enabled subcutaneous formulations.
High Profitability and EPS Expansion
Adjusted EBITDA of $229.5M (up ~42% YoY) and non-GAAP diluted EPS of $1.60 (vs $1.11 prior year), representing a >40% increase year-over-year; GAAP diluted EPS $1.22 (vs $0.93).
Reaffirmed 2026 Guidance and Multi-Year Outlook
Reaffirmed full-year 2026 guidance: total revenue $1.71B–$1.81B (growth ~22%–30% YoY), royalty revenues $1.13B–$1.17B (30%–35% YoY), adjusted EBITDA $1.125B–$1.205B, and non-GAAP EPS $7.75–$8.25 (excluding potential buyback impact).
ENHANZE Revenue Momentum and Long-Duration Backlog
Company estimates the 10 approved ENHANZE products had generated ~25% of projected royalties by end-2025 and that ~66% of the additional projected royalty revenue remains to come between 2026–2032, implying substantial multi-year upside.
Strong Product-Level Performance
DARZALEX: ~$4B global sales in Q1 (+~18% operational growth) producing $129M royalty revenue (+26% YoY). VYVGART Hytrulo: ~$1.3B global sales (+~63% YoY) producing $46.3M royalties (+119% YoY). PHESGO: CHF686M (~$877M) sales (+27% YoY) producing $30.2M royalties (+25% YoY).
Pipeline and Deal Momentum
Up to 13 additional ENHANZE pipeline products projected to be in development by end-2026 (potential launches 2029+). Signed three new collaboration/licensing agreements in 2026 (including GSK, Vertex, ORKA), and two partners initiated new Phase I ENHANZE studies in Q1 aligned with 6 Phase I starts expected in 2026.
Hypercon and Longer-Term Growth Drivers
Hypercon: first two Phase I clinic starts now projected in H1 2027 with launches targeted 2030–2031; company projects Hypercon could drive ~ $1B in royalty revenue by mid-2030s. Hypercon already has CLAs with 5 companies covering 17 potential targets.
Shareholder Returns and Capital Allocation
Announced a new $1.0B share repurchase authorization with an expectation to buy back at least $400M in 2026 and a projected ~3% annual buyback yield over coming years; capital priorities also include reinvestment in organic programs and deleveraging (plan to retire 2027/2028 notes at maturity).
Operational Leverage and Cash Conversion
Management highlights efficient conversion of revenue to free cash flow, supporting buybacks, debt paydown and disciplined reinvestment in core businesses (ENHANZE, Hypercon, Surf Bio).
HALO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HALO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 11, 2026 | $66.41 | $70.93 | +6.81% |
Feb 17, 2026 | $80.48 | $73.23 | -9.01% |
Nov 03, 2025 | $66.20 | $68.05 | +2.79% |
Aug 05, 2025 | $60.81 | $62.32 | +2.48% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Halozyme Therapeutics (HALO) report earnings?
Halozyme Therapeutics (HALO) is schdueled to report earning on Aug 11, 2026, After Close (Confirmed).
What is Halozyme Therapeutics (HALO) earnings time?
Halozyme Therapeutics (HALO) earnings time is at Aug 11, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HALO EPS forecast?
HALO EPS forecast for the fiscal quarter 2026 (Q2) is 1.81.